themuzicmen, two possible outcomes IMO within the next 6 to 12 months
1. GE/Aldevron/Defense Department contract(s) or other collaboration(s) lead to CYGX revenue, even if it's only 6 figures, we're on the right track with a promising future for synDNA technology
2. No major changes in CYGX position, no revenue, no financing, CYGX continues to issue more PPOs diluting our value and continues to ask stockholders to support their continued "efforts" to make synDNA and related vaccines viable in the marketplace.
If #1 happens, we're flying
If #2 happens, I may consider selling part of my CYGX position and put my money elsewhere. Maybe maintain some CYGX as high risk potential, but the stock will no longer be a speculative buy, IMO
In other words, we can thank GE and Aldevron for whichever happens, synDNA either works or it doesn't. Hanging in there for another 6 to 12 months is fine with me.